Advanced search
Publication Cover
Pathology Volume 40, 2008 - Issue 3
Submit an article Journal homepage
5
Views
0
CrossRef citations to date
0
Altmetric
Review

What's in a cancer syndrome? Genes, phenotype and pathology

Nicola Wayte The Queensland Institute of Medical Research, Brisbane; School of Molecular and Microbial Sciences
,
Leonard Da Silva The Queensland Institute of Medical Research, Brisbane; Molecular and Cellular Pathology, School of Medicine, University of Queensland, BrisbaneCorrespondence[email protected]
,
Georgia Chenevix-Trench The Queensland Institute of Medical Research, Brisbane
&
Sunil R. Lakhani The Queensland Institute of Medical Research, Brisbane; Molecular and Cellular Pathology, School of Medicine, University of Queensland, Brisbane; Pathology Queensland, The Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
Pages 247-259 | Received 04 Oct 2007, Accepted 08 Oct 2007, Published online: 06 Jul 2009

References

  • Jass J R. Familial cancer: Histopathological perspectives. J Clin Pathol 1997; 50: 892–895
  • R A Eeles, Easton, D F, Ponder, B AJ, Eng, C. Genetic Predisposition to Cancer. London, Arnold. 2004
  • Dunn J M, Phillips R A, Becker A J, et al. Identification of germline and somatic mutations affecting the retinoblastoma gene. Science 1988; 241: 1797–1800
  • Friend S H, Bernards R, Rogelj S, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 1986; 323: 643–646
  • Tomlinson I P, Roylance R, Houlston R S. Two hits revisited again. J Med Genet 2001; 38: 81–85
  • Fearon E R. Human cancer syndromes: clues to the origin and nature of cancer. Science 1997; 278: 1043–1050
  • Galiatsatos P, Foulkes W D. Familial adenomatous polyposis. Am J Gastroenterol 2006; 101: 385–398
  • H JR Bussey. Familial polyposis coli: family studies, histopathology, differential diagnosis, and results of treatment. Baltimore, Johns Hopkins University Press. 1975
  • Knudsen A L, Bisgaard M L, Bulow S. Attenuated familial adenomatous polyposis (AFAP). A review of the literature. Fam Cancer 2003; 2: 43–55
  • Lal G, Gallinger S. Familial adenomatous polyposis. Semin Surg Oncol 2000; 18: 314–323
  • Bulow S, Alm T, Fausa O, et al. Duodenal adenomatosis in familial adenomatous polyposis. DAF project group. Int J Colorectal Dis 1995; 10: 43–46
  • Church J M, Mcgannon E, Hull-Boiner S, et al. Gastroduodenal polyps in patients with familial adenomatous polyposis. Dis Colon Rectum 1992; 35: 1170–1173
  • Knudsen A L, Bulow S. Desmoid tumour in familial adenomatous polyposis. A review of literature. Fam Cancer 2001; 1: 111–119
  • Powell S M, Petersen G M, Krush A J, et al. Molecular diagnosis of familial adenomatous polyposis. N Engl J Med 1993; 329: 1982–1987
  • Van Der Luijt R B, Khan P M, Vasen H F, et al. Molecular analysis of the apc gene in 105 dutch kindreds with familial adenomatous polyposis: 67 germline mutations identified by DGGE, PTT, and southern analysis. Hum Mutat 1997; 9: 7–16
  • Marsh D, Zori R. Genetic insights into familial cancers—update and recent discoveries. Cancer Lett 2002; 181: 125–164
  • Lynch H T, De La Chapelle A. Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet 1999; 36: 801–818
  • Cetta F, Montalto G, Gori M, et al. Germline mutations of the apc gene in patients with familial adenomatous polyposis-associated thyroid carcinoma: Results from a european cooperative study. J Clin Endocrinol Metab 2000; 85: 286–292
  • Giardiello F M, Offerhaus G J, Lee D H, et al. Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis. Gut 1993; 34: 1394–1396
  • Giardiello F M, Petersen G M, Brensinger J D, et al. Hepatoblastoma and APC gene mutation in familial adenomatous polyposis. Gut 1996; 39: 867–869
  • Kadmon M, Tandara A, Herfarth C. Duodenal adenomatosis in familial adenomatous polyposis coli. A review of the literature and results from the heidelberg polyposis register. Int J Colorectal Dis 2001; 16: 63–75
  • Lynch H T, Boland C R, Gong G, et al. Phenotypic and genotypic heterogeneity in the lynch syndrome: Diagnostic, surveillance and management implications. Eur J Hum Genet 2006; 14: 390–402
  • Lynch H T, Lynch J F. Hereditary nonpolyposis colorectal cancer. Semin Surg Oncol 2000; 18: 305–313
  • Lynch H T, Smyrk T C, Watson P, et al. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: An updated review. Gastroenterology 1993; 104: 1535–1549
  • Lynch H T, Krush A J. Cancer family “G” revisited: 1895–1970. Cancer 1971; 27: 1505–1511
  • Hamilton S R, Liu B, Parsons R E, et al. The molecular basis of Turcot's syndrome. N Engl J Med 1995; 332: 839–847
  • Akiyama Y, Sato H, Yamada T, et al. Germ-line mutation of the hMSH6/GTBP gene in an atypical hereditary nonpolyposis colorectal cancer kindred. Cancer Res 1997; 57: 3920–3923
  • Bronner C E, Baker S M, Morrison P T, et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 1994; 368: 258–261
  • Fishel R, Lescoe M K, Rao M R, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993; 75: 1027–1038
  • Leach F S, Nicolaides N C, Papadopoulos N, et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 1993; 75: 1215–1225
  • Miyaki M, Konishi M, Tanaka K, et al. Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nat Genet 1997; 17: 271–272
  • Nicolaides N C, Papadopoulos N, Liu B, et al. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 1994; 371: 75–80
  • Papadopoulos N, Nicolaides N C, Wei Y F, et al. Mutation of a mutL homolog in hereditary colon cancer. Science 1994; 263: 1625–1629
  • Peltomaki P, Vasen H F. Mutations predisposing to hereditary nonpolyposis colorectal cancer: Database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology 1997; 113: 1146–1158
  • Parsons R, Li G M, Longley M J, et al. Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell 1993; 75: 1227–1236
  • Hemminki A, Peltomaki P, Mecklin J P, et al. Loss of the wild type MLH1 gene is a feature of hereditary nonpolyposis colorectal cancer. Nat Genet 1994; 8: 405–410
  • Shashidharan M, Smyrk T, Lin K M, et al. Histologic comparison of hereditary nonpolyposis colorectal cancer associated with MSH2 and MLH1 and colorectal cancer from the general population. Dis Colon Rectum 1999; 42: 722–726
  • Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999; 81: 214–218
  • Millar A L, Pal T, Madlensky L, et al. Mismatch repair gene defects contribute to the genetic basis of double primary cancers of the colorectum and endometrium. Hum Mol Genet 1999; 8: 823–829
  • Vasen H F, Watson P, Mecklin J P, et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology 1999; 116: 1453–1456
  • Dunlop M G, Farrington S M, Carothers A D, et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 1997; 6: 105–110
  • Froggatt N J, Green J, Brassett C, et al. A common MSH2 mutation in English and north American HNPCC families: origin, phenotypic expression, and sex specific differences in colorectal cancer. J Med Genet 1999; 36: 97–102
  • Vasen H F, Wijnen J T, Menko F H, et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996; 110: 1020–1027
  • Beck N E, Tomlinson I P, Homfray T, et al. Genetic testing is important in families with a history suggestive of hereditary non-polyposis colorectal cancer even if the Amsterdam criteria are not fulfilled. Br J Surg 1997; 84: 233–237
  • Umar A, Boland C R, Terdiman J P, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004; 96: 261–268
  • Easton D F. Familial risks of breast cancer. Breast Cancer Res 2002; 4: 179–181
  • Antoniou A, Pharoah P D, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117–1130
  • Chappuis P O, Nethercot V, Foulkes W D. Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. Semin Surg Oncol 2000; 18: 287–295
  • Phillips K A, Andrulis I L, Goodwin P J. Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2:are they prognostically different?. J Clin Oncol 1999; 17: 3653–3663
  • Lakhani S R, Jacquemier J, Sloane J P, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998; 90: 1138–1145
  • Breast Cancer Linkage Consortium. Pathology of familial breast cancer: Differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 1997; 349: 1505–1510
  • Lakhani S R, Van De Vijver M J, Jacquemier J, et al. The pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002; 20: 2310–2318
  • Bishop D T, Demenais F, Goldstein A M, et al. Geographical variation in the penetrance of CDKN2a mutations for melanoma. J Natl Cancer Inst 2002; 94: 894–903
  • Ford D, Bliss J M, Swerdlow A J, et al. Risk of cutaneous melanoma associated with a family history of the disease. The International Melanoma Analysis Group (IMAGE). Int J Cancer 1995; 62: 377–381
  • Tucker M A, Goldstein A M. Melanoma etiology: Where are we?. Oncogene 2003; 22: 3042–3052
  • Hussussian C J, Struewing J P, Goldstein A M, et al. Germline p16 mutations in familial melanoma. Nat Genet 1994; 8: 15–21
  • Kamb A, Shattuck-Eidens D, Eeles R, et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 1994; 8: 23–26
  • Zuo L, Weger J, Yang Q, et al. Germline mutations in the p16ink4a binding domain of cdk4 in familial melanoma. Nat Genet 1996; 12: 97–99
  • Lilischkis R, Sarcevic B, Kennedy C, et al. Cancer-associated mis-sense and deletion mutations impair p16ink4 cdk inhibitory activity. Int J Cancer 1996; 66: 249–254
  • Monzon J, Liu L, Brill H, et al. CDKN2a mutations in multiple primary melanomas. N Engl J Med 1998; 338: 879–887
  • Pho L, Grossman D, Leachman S A. Melanoma genetics: a review of genetic factors and clinical phenotypes in familial melanoma. Curr Opin Oncol 2006; 18: 173–179
  • Li F P, Fraumeni J F, Jr. Rhabdomyosarcoma in children: Epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst 1969; 43: 1365–1373
  • Li F P, Fraumeni J F, Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?. Ann Intern Med 1969; 71: 747–752
  • Nichols K E, Malkin D, Garber J E, et al. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev 2001; 10: 83–87
  • Li F P, Fraumeni J F, Jr, Mulvihill J J, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988; 48: 5358–5362
  • Lynch H T, Mulcahy G M, Harris R E, et al. Genetic and pathologic findings in a kindred with hereditary sarcoma, breast cancer, brain tumors, leukemia, lung, laryngeal, and adrenal cortical carcinoma. Cancer 1978; 41: 2055–2064
  • Tomlinson M J, Bullimore J A. Adrenal-cell carcinoma and rhabdomyosarcoma occurring in father and daughter: ‘SBLA’ syndrome?. Br J Radiol 1987; 60: 89–90
  • Birch J M, Alston R D, McNally R J, et al. Relative frequency and morphology of cancers in carriers of germline tp53 mutations. Oncogene 2001; 20: 4621–4628
  • Hartley A L, Birch J M, Tricker K, et al. Wilms' tumor in the Li-Fraumeni cancer family syndrome. Cancer Genet Cytogenet 1993; 67: 133–135
  • Nichols K E, Malkin D, Garber J E, et al. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev 2001; 10: 83–87
  • Strong L C, Stine M, Norsted T L. Cancer in survivors of childhood soft tissue sarcoma and their relatives. J Natl Cancer Inst 1987; 79: 1213–1220
  • Varley J M, McGown G, Thorncroft M, et al. Germ-line mutations of tp53 in Li-Fraumeni families: An extended study of 39 families. Cancer Res 1997; 57: 3245–3252
  • Hwang S J, Lozano G, Amos C I, et al. Germline p53 mutations in a cohort with childhood sarcoma: Sex differences in cancer risk. Am J Hum Genet 2003; 72: 975–983
  • Garber J E, Offit K. Hereditary cancer predisposition syndromes. J Clin Oncol 2005; 23: 276–292
  • Hisada M, Garber J E, Fung C Y, et al. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 1998; 90: 606–611
  • Varley J M. Germline tp53 mutations and Li-Fraumeni syndrome. Hum Mutat 2003; 21: 313–320
  • Frebourg T, Barbier N, Yan Y X, et al. Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome. Am J Hum Genet 1995; 56: 608–615
  • Bougeard G, Limacher J M, Martin C, et al. Detection of 11 germline inactivating tp53 mutations and absence of tp63 and HCHK2 mutations in 17 French families with Li-Fraumeni or Li-Fraumeni-like syndrome. J Med Genet 2001; 38: 253–257
  • Birch J M, Hartley A L, Tricker K J, et al. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 1994; 54: 1298–1304
  • Eeles R A. Germline mutations in the tp53 gene. Cancer Surv 1995; 25: 101–124
  • Pilarski R, Eng C. Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome. J Med Genet 2004; 41: 323–326
  • Starink T M, Van Der Veen J P, Arwert F, et al. The Cowden syndrome: A clinical and genetic study in 21 patients. Clin Genet 1986; 29: 222–233
  • Eng C. Will the real Cowden syndrome please stand up: Revised diagnostic criteria. J Med Genet 2000; 37: 828–830
  • Nelen M R, Kremer H, Konings I B, et al. Novel PTEN mutations in patients with Cowden disease: Absence of clear genotype-phenotype correlations. Eur J Hum Genet 1999; 7: 267–273
  • Nelen M R, Van Staveren W C, Peeters E A, et al. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum Mol Genet 1997; 6: 1383–1387
  • Nelen M R, Padberg G W, Peeters E A, et al. Localisation of the gene for Cowden disease to chromosome 10q22–23. Nat Genet 1996; 13: 114–116
  • Liaw D, Marsh D J, Li J, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997; 16: 64–67
  • Marsh D J, Dahia P L, Zheng Z, et al. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet 1997; 16: 333–334
  • Brownstein M H, Wolf M, Bikowski J B. Cowden's disease: A cutaneous marker of breast cancer. Cancer 1978; 41: 2393–2398
  • Riccardi V M. Von Recklinghausen neurofibromatosis. N Engl J Med 1981; 305: 1617–1627
  • Basu T N, Gutmann D H, Fletcher J A, et al. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 1992; 356: 713–715
  • Lazaro C, Ravella A, Gaona A, et al. Neurofibromatosis type 1 due to germ-line mosaicism in a clinically normal father. N Engl J Med 1994; 331: 1403–1407
  • Littler M, Morton N E. Segregation analysis of peripheral neurofibromatosis (NF1). J Med Genet 1990; 27: 307–310
  • Riccardi V M, Lewis R A. Penetrance of von Recklinghausen neurofibromatosis: A distinction between predecessors and descendants. Am J Hum Genet 1988; 42: 284–289
  • National Institutes of Health Consensus Development Conference Statement: Neurofibromatosis. Bethesda, USA, July 13–15, 1987. Neurofibromatosis 1988; 1: 172–178
  • Yohay K. Neurofibromatosis types 1 and 2. Neurologist 2006; 12: 86–93
  • Evans D G, Huson S M, Donnai D, et al. A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet 1992; 29: 841–846
  • Bouzas E A, Freidlin V, Parry D M, et al. Lens opacities in neurofibromatosis 2:Further significant correlations. Br J Ophthalmol 1993; 77: 354–357
  • Rouleau G A, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 1993; 363: 515–521
  • Trofatter J A, Maccollin M M, Rutter J L, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993; 72: 791–800
  • Sestini R, Vivarelli R, Balestri P, et al. Neurofibromatosis type 2 attributable to gonosomal mosaicism in a clinically normal mother, and identification of seven novel mutations in the NF2 gene. Hum Genet 2000; 107: 366–371
  • Narod S A, Parry D M, Parboosingh J, et al. Neurofibromatosis type 2 appears to be a genetically homogeneous disease. Am J Hum Genet 1992; 51: 486–496
  • Baser M E, Kuramoto L, Woods R, et al. The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2. J Med Genet 2005; 42: 540–546
  • Evans D G, Sainio M, Baser M E. Neurofibromatosis type 2. J Med Genet 2000; 37: 897–904
  • Joenje H, Patel K J. The emerging genetic and molecular basis of Fanconi anaemia. Nat Rev Genet 2001; 2: 446–457
  • Alter B P. Fanconi's anemia. Current concepts. Am J Pediatr Hematol Oncol 1992; 14: 170–176
  • Alter B P. Cancer in Fanconi anemia, 1927–2001. Cancer 2003; 97: 425–440
  • Fanconi G. Familial constitutional panmyelocytopathy, Fanconi's anemia (FA). I. Clinical aspects. Semin Hematol 1967; 4: 233–240
  • Tischkowitz M D, Hodgson S V. Fanconi anaemia. J Med Genet 2003; 40: 1–10
  • Alter B P. Fanconi's anaemia and its variability. Br J Haematol 1993; 85: 9–14
  • Faivre L, Guardiola P, Lewis C, et al. Association of complementation group and mutation type with clinical outcome in Fanconi anemia. European Fanconi Anemia Research Group. Blood 2000; 96: 4064–4070
  • Joenje H, Oostra A B, Wijker M, et al. Evidence for at least eight Fanconi anemia genes. Am J Hum Genet 1997; 61: 940–944
  • Wang X, Andreassen P R, D'Andrea A D. Functional interaction of monoubiquitinated FANCD2 and BRCA2/FANCD1 in chromatin. Mol Cell Biol 2004; 24: 5850–5862
  • Mathew C G. Fanconi anaemia genes and susceptibility to cancer. Oncogene 2006; 25: 5875–5884
  • Poole S R, Smith A C, Hays T, et al. Monozygotic twin girls with congenital malformations resembling Fanconi anemia. Am J Med Genet 1992; 42: 780–784
  • Nagy R, Sweet K, Eng C. Highly penetrant hereditary cancer syndromes. Oncogene 2004; 23: 6445–6470
  • Bowles Biesecker B, Marteau T M. The future of genetic counselling: an international perspective. Nat Genet 1999; 22: 133–137

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.